Biotech giant Illumina says it will undo its $7.1 billion purchase of the cancer-screening company Grail VERBATIM: San Diego-based Illumina says it made its decision to divest after a U.S. appeals court recently ruled that the merger could violate antitrust laws. The European Union in October ordered the deal to unwind because it closed in […]
Audio
Illumina to undo $7.1 billion purchase of cancer-screening company Grail
Biotech giant Illumina says it will undo its $7.1 billion purchase of the cancer-screening company Grail
VERBATIM: San Diego-based Illumina says it made its decision to divest after a U.S. appeals court recently ruled that the merger could violate antitrust laws. The European Union in October ordered the deal to unwind because it closed in 2021 without approval from regulators in the 27-nation bloc. Illumina says it will complete the divestment next year.